Sun, Aug 31, 2014, 6:05 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cubist Pharmaceuticals Inc. Message Board

  • stevencath@sbcglobal.net stevencath Aug 23, 2009 9:37 PM Flag

    CUBIST PHARM. BEST BUY know $20 TO $30 this year------STRONG BUY----

    ---Last year I sent TOP Officers-5 at Astra Zeneca—5 at Novatis AG( CEO,PRES. and VP ect) this is what I sent them in the letter.
    Cubist Pharm.***it’s drug CUBICIN is growing fast 25% to 35% per qtr , and (CBST)already has COMPENTITION ON and still grows fast—(at some point up to 1 Bill sales) it sold $280 Mill 07--$435 Mill 08 and est.09$540 to560 Mill. Also (CBST) will have $515 Mill cash at the end of this year. (CBST)also has other drugs it’s working on---2 in Phase II—2 in Phase I—also (CBST) is selling Aztrazeneca’s (MERREM drug) in the US
    Novartis AG bought three companies in 07---Mycograb,Aurograb and Tifacogin , now in 08 Protez at $ 300 Mill—for there drug is in phase II and wont be ready until ( if it works) until 2012---
    ------Now Novartis is ok and ready to launch CUBICIN in Turkey,Russia,Mexico,Brazil,Australia,New Zealand. This is huge---
    ------AstraZeneca sells its drug (MERREM)in the US with (CBST). AstraZeneca is now getting an OK to sell CUBICIN in CHINA---(CHINA is three time bigger than the US). AstraZeneca also is going to sell CUBICIN in Asia,Middle East,and Africa
    -----I think both Novartis AG and AstraZeneca each will end going after (CBST)—AstraZeneca sells MERREM drug in the US with (CBST) and possibly selling CUBICIN in CHINA and other countries. Then with Novartis it will be selling CUBICIN around the world-----Then these companys pay (CBST) 30% on sells of CUBICIN out of the US.
    A) (CBST) will have over $500 Mill cash the end of 09
    B) (CBST) is working on 4 other drugs , 2 on phase II, AND 2 drugs phase I
    C) (CBST) is selling CUBICIN in the US and is 25% to 35% per qtr growth (UP TO 1 Bill at some port soon)
    I think the company (CBST) is going to go bought out higher than figured--$36 to $38----(P/E 25 at this years earnings est.$1.50 is $37.50)
    Cubist is going to make 25% to 35% per qtr in the US with competition now ( 4 now and another with possibly Theravance ) Theravance possibly( if OK’d to sell) not to sell to pregnanted woman or young Babies.---------Also CUBICIN is growing selling against taking main ---competition ---Vancomycin that genereic antibiotic and has long been the treatment of last resort. I don’t get this -----we are working about TEVA Pharm. and has to court in thirty months (which CBST is covered by PATENDED)
    What I’m getting out is ----(CBST) will sell CUBICIN in the US a lot of each qtr
    and make 30% on sell in othere countrys-----also Phizer Inc drug company and Vancomycin generic drug are the largist companys in competition with CUBIST and (CBST) is in high growth 25% to 35% per qtr.
    BY SWNV

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CBST
69.03+0.12(+0.17%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.